Skip to main content
Rebecca Gardner
Rebecca Gardner, MD

Rebecca Gardner, MD

Associate Member, St. Jude Faculty

  • Director, Oncology Cellular Therapy
  • Medical Director, Children’s GMP, LLC Cellular Therapy Program



BS – Bates College, Lewiston, ME
MD – University of Maryland School of Medicine, Baltimore, MD
Residency (Pediatrics) – University of Utah, Salt Lake City, UT
Fellowship (Pediatric Hematology/Oncology) – University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA

Honors & Awards

2006 Residency Teaching Award, University of Utah
2011 Alex’s Lemonade Stand – Young Investigator Award
2013 Conquer Cancer Foundation – Career Development Award
2021 Attending Teaching Award – Pediatric Hematology/Oncology Fellowship, University of Washington

Research Interests

Development of cellular immunotherapy trials for pediatric cancer

Selected Publications

Adams C, Keller M, Michlitsch JG, Aguayo-Hiraldo P, Chen K, Hossain MZ, Davis A, Park JR, Verneris MR, Gardner RA. Development of a Safety Surveillance Plan for the Academic Medicine Sponsor Performing First-in-Human Cellular Therapy Clinical Trials: A Report from the Consortium for Pediatric Cellular Immunotherapy. Transplant Cell Ther. 2024 May;30(5):475-487. doi: 10.1016/j.jtct.2024.02.022. Epub 2024 Mar 4. PMID: 38447751.

Holland EM, Yates B, Steinberg SM, Yuan CM, Wang HW, Annesley C, Shalabi H, Stroncek D, Fry TJ, Krueger J, Jacoby E, Hsieh E, Bhojwani D, Gardner RA, Maude SL, Shah NN.  Chimeric Antigen Receptor T cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure. Cell Transplant Ther Sep,29(9):574, 2023. PMID: 37394115

McNerney KO, Hsieh EM, Shalabi H, Epperly R, Wolters PL, Hill JA, Gardner R, Talleur AC, Shah NN, Rossoff J. INSPIRED Symposium Part 3: Prevention and Management of Pediatric CAR T cell-Associated Emergent Toxicities. Transplant Cell Ther Oct9:S2666-6367(23)01587-7, 2023. PMID 37821079

Lee BM, Summers C, Chisholm KM, Bohling SD, Leger KJ, Gardner R, Annesley C, Lamble AJ. Plasticity of lineage switch in B-ALL allows for successful rechallenge with CD19-directed immunotherapy. Blood Adv Jun 27,7(12):2825-2830, 2023. PMID:36763522

Hill JA, Kiem ES, Bhatti A, Liu W, Keane-Candib J, Fitzpatrick KS, Boonyaratanakornkit J, Gardner RA, Green DJ, Maloney DG, Turtle CJ, Smith JM, Gimferrer I, Blosser CD, Jackson SW. Anti-HLA antibodies in recipients of CD19 versus BCMA-targeted CAR T-cell therapy. Am J Transplant Mar,23(3):416-422, 2023. PMID: 36748802

Nikiforow S, Frigault MJ, Frey NV, Gardner RA, Komanduri KV, Perales MA, Kebriaei P, Warkentin PI, Pasquini M, Aho JL, Levine BL, Heslop HE, Hlucky TL, Habucky K, Gharibo M, Jagasia M, Locke FL. Paving the Road for CAR-Ts: ASTCT 80/20 Task Force consensus on challenges and solutions to improving efficiency of clinical center certification and maintenance of operations for commercially approved immune effector cell therapies. Transplant Cell Ther Jan 26:S2666-6367, 2023. PMID: 36709800

Gardner RA, Sha NN. CAR T-Cells for Cure in Pediatric B-ALL. J Clin Oncol Mar 20,41(9):1646-1648, 2023. PMID: 36634289

Mashih KE, Gardner RA, Chou HC, Abdelmaksoud A, Song YK, Mariani L, Gangalapudi V, Gryder BE, Wilson AL, Adebola SO, Stanton BZ, Wang C, Milewski D, Kim YY, Tian M, Cheuk ATC, Wen X, Zhang Y, Altan-Bonnet G, Kelly MC, Wei JS, Bulyk ML, Jensen MC, Orentas RJ, Khan J.  A stem cell epigenome is associated with primary non-response to CD19 CAR T-cells in pediatric acute lymphoblastic leukemia. Blood Adv Aug 8,7(15):4218-4232, 2023. PMID: 36607839

Vitanza NA, Ronsley R, Choe M, Henson C, Breedt M, Barrios-Anderson A, Wein A, Brown C, Beebe A, Kong A, Kirkey D, Lee BM, Leary SES, Crotty EE, Hoeppner C, Holtzclaw S, Wilson AL, Gustafson JA, Foster JB, Iliff JJ, Goldstein HE, Browd SR, Lee A, Ojemann JG, Pinto N, Gust J, Gardner RA, Jensen MC, Hauptman JS, Park JR. Locoregional CAR T cells for children with CNS tumors: Clinical procedure and catheter safety. Neoplasia Feb:36:100870, 2023.  PMID: 36599192

Vitanza NA, Wilson AL, Huang W, Seidel K, Brown C, Gustafson JA, Yokoyama JK, Johnson AJ, Baxter BA, Koning RW, Reid AN, Meechan M, Biery MC, Myers C, Rawlings-Rhea SD, Albert CM, Browd SR, Hauptman JS, Lee A, Ojemann JG, Berens ME, Dun MD, Foster JB, Crotty EE, Leary SES, Cole BL, Perez FA, Wright JN, Orentas RJ, Chour T, Newell EW, Whiteaker JR, Zhao L, Paulovich AG, Pinto N, Gust J, Gardner RA, Jensen MC, Park JR. Intraventricular B7-H3 CAR T cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety. Cancer Discov Jan 9,13(1):114-131, 2023. PMID: 36259971

Gust J, Rawlings-Rhea SD, Wilson AL, Tulberg NM, Sherman AL, Seidel KD, Wu QV, Park JR, Gardner RA, Annesley CE. “GFAP and NfL increase during neurotoxicity from high baseline levels in pediatric CD19-CAR T-cell patients. Blood Adv Mar 28,7(6):1001-1010, 2022. PMID: 36006611

Whitlock, J, Malvar, J, Dalla-Pozza L, Silverman, L, Ziegler, D, Brown P, Gardner R, Gaynon P, Huynh V, Jeha S, Marcus L, Messinger Y, Schultz K, Cassar J, Locatelli F, Zwaan D, Wood B, Sposto R, Gore L. Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma (Study T2008-002 NECTAR). Ped Blood Cancer Nov,69(11), 2022. PMID: 35989458

Hsieh EM, Myers RM, Yates B, Annesley C, John S, Taraseviciute A, Steinberg SM, Sheppard J, Chung P, Chen L, Lee DW, DiNofia A, Grupp SA, Verneris MR, Laetsch TW, Bhojwani D, Brown PA, Pulsipher MA, Rheingold SR, Gardner RA, Gore L, Shah NN, Lamble AJ. Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy. Blood Adv Sep 13,6(17):5222-5226, 2022. PMID 35834728

Ceppi F, Wilson AL, Annesley C, Summers C, Brand A, Seidel K, Wu QV, Rawlings-Rhea S, Huang W, Pulsipher MA, Wayne AS, Park JR, Jensen MC, Gardner RA. Modified manufacturing process modulates CD19CAR T-cell engraftment fitness and leukemia-free survival in pediatric and young adult subjects. Cancer Immunol Res Jul 1,10(7):856-870, 2022. PMID: 35580141

Lamble A, Myers RM, Taraseviciute A, John S, Yates B, Steinberg SM, Sheppard J, Kovach AE, Wood B, Borowitz MJ, Stetler-Stevenson M, Yuan CM, Pillai V, Foley T, Chung P, Chen L, Lee DW, Annesley C, DiNofia A, Grupp SA, Verneris MR,  Gore L, Laetsch TW, Bhojwani D, Brown PA, Pulsipher MA, Rheingold SR, Gardner RA, Shah NN. Pre-infusion factors impacting relapse immunophenotype following CD19 CAR T-cells. Blood Adv Feb 28,7(4):575-585, 2022. PMID: 35482927

Diorio C, Vatsayan A, Talleur AC, Annesley C, Jaroscak JJ, Shalabi H, Ombrello AK, Hudspeth M, Maude SL, Gardner RA, Shah NN.  Anakinra utilization in refractory pediatric CAR T-cell associated toxicities.  Blood Adv Jun 14,6(11):3398-3403, 2022 PMID: 35395068

Summers C, Wu QV, Annesley C, Bleakley M, Dahlberg A, Narayanaswamy P, Huang W, Voutsinas J, Brand A, Leisenring W, Jensen MC, Park JR, Gardner RA. Hematopoietic cell transplantation after CAR T cell induced remission confers leukemia-free survival advantage” Transplant Cell Ther Jan;28(1):21-29, 2022. PMID: 34644605

Myers, RM, Taraseviciute, A, Steinberg, SM, Lamble, AJ, Sheppard, J, Yates, B, Kovach, AE, Wood, B, Borowitz, MJ, Stetler-Stevenson M, Yuan CM, Pillai V,  Foley T, Chung P, Chen L, Lee DW, Annesley C, DiNofia A, Grupp SA, John S, Bhojwani D, Brown PA, Laetsch TW, Gore L, Gardner RA, Rheingold SR, Pulsipher MA, Shah N. Blinatumomab Nonresponse and High Disease Burden Are Associated With Inferior outcomes After CD19-CAR for B-ALL. JCO Mar 20;40(9):932-944, 2021. PMID: 34767461

Walti CS, Loes AN, Shuey K, Krantz EM, Boonyaratanakornkit J, Keane-Candib J, Loeffelholz T, Wolf CR, Taylor JJ, Gardner RA, Green DJ, Cowan AJ, Maloney DG, Turtle CJ, Pergam SA, Chu HY, Bloom JD, Hill JA. Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy. J Immunother Cancer Oct;9(10):e003428, 2021. PMID: 34702753

Lichtenstein DA, Schischlik F, Shao L, Steinberg SM, Yates B, Want HW, Ceppi F, Hermida LC, Wang Y, Inglefied J, Rampertaap S, Robinson W, Chisholm KM, Yuan C, Stetler-Stevenson M, Ombrello AK, Rosenzweig S, Jin J, Fry TJ, Highfill SL, Jin P, Shalabi H, Gardner R, Ruppin E, Stroncek DF, Shah NN. Characterizations of HLH-Like Manifestations as a CRS Variant in Patients Receiving CD22 CAR-T cells. Blood Dec 16;138(24):2469-2484, 2021. PMID: 34525183

Vitanza NA, Johnson AJ, Wilson AL, Brown C, Yokoyama JK, Kunkele A, Chang CA, Rawlings-Rhea S, Huang W, Seidel K, Albert CM, Pinto N, Gust J, Finn LS, Ojemann JG, Wright J, Orentas RJ, Baldwin M, Gardner RA, Jensen MC, Park JR. Locoregional infusion of HER2-specific CAR T cells: preclinical design to interim report of the ongoing trial BrainChild-01 for children with recurrent/refractory CNS tumors. Nat Med Sept 27(9):1544-1552, 2021. PMID: 34253928

Walti CS, Krantz EM, Maalouf J, Boonyaratanakornkit J, Keane-Candib J, Joncas-Schronce L, Steverns-Ayers T, Dasgupta S. Taylor JJ, Hirayama AV, Bar M, Gardner RA, Green DJ, Boeckh MJ, Maloney DG, Turtle CJ, Hill JA.  Antibodies to Vaccine-Preventable Infections after CAR T-cell Therapy for B-Cell Malignancies. JCI Insight Jun 8;6(11:146743, 2021. PMID: 33914708

Shalabi H, Gust J, Taraseviciute A, Woleters P, Leahy A, Sandi C, Laetsch T, Wiener L, Gardner R, Nussenblatt V, Hill J, Curran K, Olson T, Annesley C, Want HW, Khan J, Pasquini M, Duncan C, Grupp S, Pulsipher M, Shah N. Beyond the storm: extended toxicities and late effects in children receiving CAR T cells. Nat Rev Clinical Oncol Jun;18(6):363-378, 2021. PMID: 33495553

Lamble A, Gardner RA. CAR-T Cells for Other Pediatric Hematological Malignancies Including AML, Hematology Am Soc Hematol Educ Program Dec 4;2020(1):494-500, 2020.  PMID: 33275678

Mo G, Wang HW, Talleur A, Shahani S, Yates B, Shalabi H, Douvas M, Calvo K, Shern J, Chaganti S, Patrick K, Young S, Fry T, Wu X, Triplett B, Khan J, Gardner R, Shah N. Diagnostic Approach to the Evaluation of Myeloid Malignancies Following CAR T-cell Therapy in B-Cell Acute Lymphoblastic Lymphoma, J Immunother Cancer Nov;8(2):e001563, 2020. PMID: 33246985

Davies K, Barth M, Armenian S, Audino AN, Barnete P, Cuglievan B, Ding H, Ford JB, Galardy PJ, Gardner R, Hanna R, Hayashi R, Kovach AE, Machnitz AJ, Maloney KW, Marks L, Page K, Reily AF, Weinstein JL, Xavier AC, McMllina NR, Freedman-Cass DA. Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Guidelines. J Natl Compr Canc Netw Aug;18(8):1105-1123, 2020. PMID: 32755986

Vora SB, Waghmare A, Englund JA, Qu P, Gardner RA, Hill JA.  Infectious complications following CD19 Chimeric Antigen Receptor T-Cell therapy for children and young adults. Open Forum Infect Dis Apr 9;7(5):ofaa121, 2020. PMID: 32432149

Denton CC, Gange WS, Abdel-Azim H, Jodele S, Kapoor N, Oberley MJ, Wong K, Kim J, Vercio A, Moghaddampour P, Chalam KV, Sierpina D, Gardner RA, Pulsipher MA, Jensen MC, Nagiel A. Bilateral retinal detachment after chimeric antigen receptor T-cell therapy. Blood Adv May 26;4(10):2158-2162, 2020. PMID:32428218

Goldberg J, Bender J, Sima J, Sulis ML, Gardner R, Pollard J, Aquino V, Laetsch T, Winick N, Fu C, Marcus L, Sun W, Verma A, Burke M, Ho P, Manley T, Mody R, Oesterheld J, Tcheng W, Thomson B, Park J, Sposto R, Messinger Y, Hijiya N, Gaynon P, Brredo J. A Phase I Study of Panobinostat In Children With Relapsed and Refractory Hematologic Malignancies. Pediatr Hematol Oncol Apr 27:1-10, 2020. PMID: 32338562

Burke MJ, Kostadinov R, Sposto R, Gore L, Kelley S, Rabik C, Trepel J, Lee MJ, Yuno A, Lee S, Bhojwani D, Jeha SC, Chang BH, Sulis ML, Hermiston ML,  Gaynon PS, Huynh V, Verma A, Gardner R, Heym KM, Dennis RM, Ziegler DS, Laetsch TW, Oesterheld JE, Duboids S, Pollard J, Glade-Bender J, Cooper T, Kaplan J, Farooqui M, Yoo B, Guest E, Wayne AS, Brown P. Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study. Clin Cancer Res May 15;26(10):2297-2307, 2020.  PMID: 31969338

Last update: March 2024